[go: up one dir, main page]

ZA917143B - Azacyclic compounds - Google Patents

Azacyclic compounds

Info

Publication number
ZA917143B
ZA917143B ZA917143A ZA917143A ZA917143B ZA 917143 B ZA917143 B ZA 917143B ZA 917143 A ZA917143 A ZA 917143A ZA 917143 A ZA917143 A ZA 917143A ZA 917143 B ZA917143 B ZA 917143B
Authority
ZA
South Africa
Prior art keywords
azacyclic compounds
azacyclic
compounds
Prior art date
Application number
ZA917143A
Inventor
Franz Ostermayer
Ostermayer Franz
Peter Herold
Herold Peter
Walter Fuhrer
Fuhrer Walter
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA917143B publication Critical patent/ZA917143B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA917143A 1990-09-10 1991-09-09 Azacyclic compounds ZA917143B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH292790 1990-09-10

Publications (1)

Publication Number Publication Date
ZA917143B true ZA917143B (en) 1992-04-29

Family

ID=4244763

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA917143A ZA917143B (en) 1990-09-10 1991-09-09 Azacyclic compounds

Country Status (12)

Country Link
EP (1) EP0475898A1 (en)
JP (1) JPH04342571A (en)
KR (1) KR920006323A (en)
AU (1) AU8375591A (en)
CA (1) CA2050769A1 (en)
FI (1) FI914228A (en)
HU (1) HUT59129A (en)
IE (1) IE913165A1 (en)
IL (1) IL99372A0 (en)
NO (1) NO913542L (en)
PT (1) PT98903A (en)
ZA (1) ZA917143B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
FR2681067B1 (en) * 1991-09-10 1993-12-17 Elf Sanofi N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
JP3290657B2 (en) * 1991-05-01 2002-06-10 メルク エンド カムパニー インコーポレーテッド Acidic aralkyltriazole derivatives active as angiotensin II antagonists
US5436259A (en) * 1991-05-10 1995-07-25 Merck & Co., Inc. Substituted 1,2,4-triazolin-3-one compounds bearing acidic functional groups as balanced angiotensin II antagonists
EP0601039A1 (en) * 1991-08-19 1994-06-15 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
JPH06510762A (en) * 1991-08-19 1994-12-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー Angiotensin 2 receptor blocking imidazolinone derivative
US5182288A (en) * 1991-11-13 1993-01-26 Ortho Pharmaceutical Corporation Substituted n-biphenylyl lactams
CA2143193A1 (en) * 1992-10-13 1994-04-28 David B. Reitz N-arylheteroarylalkyl 1-phenyl-imidazol-2-one compounds for treatment of circulatory disorders
US5411641A (en) * 1993-11-22 1995-05-02 E. I. Du Pont De Nemours And Company Electrochemical conversion of anhydrous hydrogen halide to halogen gas using a cation-transporting membrane
FR2725987B1 (en) * 1994-10-19 1997-01-10 Sanofi Sa PROCESS FOR THE PREPARATION OF A TETRAZOLE DERIVATIVE IN TWO CRYSTALLINE FORMS AND NOVEL CRYSTALLINE FORM THEREOF
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US5728834A (en) * 1996-11-14 1998-03-17 Wyckoff Chemical Company, Inc. Process for preparation of 4-aryl-1,2,4-triazol-3-ones
FR2766821A1 (en) * 1997-07-29 1999-02-05 Sanofi Sa 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES
GB9716446D0 (en) * 1997-08-05 1997-10-08 Agrevo Uk Ltd Fungicides
US6162922A (en) * 1998-01-30 2000-12-19 Bristol-Myers Squibb Co. Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
CA2339270A1 (en) 1998-08-03 2000-02-17 Yoshiharu Kinoshita Triazolone derivatives, use thereof, and intermediate therefor
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
AU2003217728B2 (en) * 2002-02-08 2008-11-20 Merck Sharp & Dohme Corp. N-Biphenylmethyl aminocycloalkanecarboxamide derivatives
TWI259079B (en) * 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
AU2003265674B2 (en) 2002-08-29 2008-12-11 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
WO2004089938A1 (en) * 2003-04-07 2004-10-21 Hetero Drugs Limited A novel crystalline form of irbesartan
US7332499B2 (en) 2003-08-07 2008-02-19 Merck & Co., Inc. Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
US20090286990A1 (en) * 2004-05-20 2009-11-19 Reguri Buchi Reddy Process for preparing irbesartan
EP1749828A1 (en) 2005-08-04 2007-02-07 Farmaprojects S.L. Process for preparing an angiotensin II receptor antagonist
WO2007052301A2 (en) * 2005-08-31 2007-05-10 Alembic Limited Process for the preparation of irbesartan
CA2604404A1 (en) 2005-10-28 2007-05-03 Alembic Limited An improved process for preparation of irbesartan
US8106216B2 (en) * 2006-04-24 2012-01-31 Aurobindo Pharma Ltd. Process for the preparation of Irbesartan
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
EP2194050A1 (en) 2008-12-08 2010-06-09 KRKA, tovarna zdravil, d.d., Novo mesto A new process for the preparation of irbesartan
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
HRP20240805T1 (en) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
CN108276389B (en) * 2018-02-09 2020-10-16 北京化工大学 A kind of synthetic method of irbesartan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
EP0409332A3 (en) * 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
EP0412594B1 (en) * 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists

Also Published As

Publication number Publication date
FI914228A (en) 1992-03-11
JPH04342571A (en) 1992-11-30
AU8375591A (en) 1992-03-12
KR920006323A (en) 1992-04-27
PT98903A (en) 1992-07-31
HU912903D0 (en) 1992-01-28
IE913165A1 (en) 1992-03-11
IL99372A0 (en) 1992-08-18
FI914228A0 (en) 1991-09-06
NO913542D0 (en) 1991-09-09
EP0475898A1 (en) 1992-03-18
CA2050769A1 (en) 1992-03-11
NO913542L (en) 1992-03-11
HUT59129A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
ZA917143B (en) Azacyclic compounds
GB9012592D0 (en) Compounds
AP9100313A0 (en) Compounds
GB9001245D0 (en) Compounds
AP9100314A0 (en) Compounds
GB9011332D0 (en) Compounds
GB9009469D0 (en) Compounds
GB9007965D0 (en) Compounds
GB9007967D0 (en) Compounds
GB9002834D0 (en) Compounds
ZA913859B (en) Azacyclic derivatives
GB9007738D0 (en) Compounds
IE892143L (en) Azacyclic compounds
ZA913166B (en) Azacyclic derivatives
GB9008507D0 (en) Compounds
GB9011850D0 (en) Compounds
GB9009480D0 (en) Compounds
GB9000049D0 (en) Compounds
GB9007984D0 (en) Compounds
GB9006449D0 (en) Compounds
GB9006112D0 (en) Compounds
GB9003640D0 (en) Compounds
GB9006111D0 (en) Compounds
GB9006109D0 (en) Compounds
GB9008872D0 (en) Compounds